{"created":"2024-11-12T05:06:12.335205+00:00","id":2000008,"links":{},"metadata":{"_buckets":{"deposit":"3d8339cf-cb2e-4ddd-b6b6-a596e323c47d"},"_deposit":{"created_by":8,"id":"2000008","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2000008"},"status":"published"},"_oai":{"id":"oai:fmu.repo.nii.ac.jp:02000008","sets":["1623632832836:1730783669761"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Suzuki, Satoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takeishi, Yasuchika","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Niizeki, Takeshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Koyama, Yo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kitahara, Tatsuro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sasaki, Toshiki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sagara, Mina","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kubota, Isao","creatorNameLang":"en"}]}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"Copyright © 2008 Mosby, Inc. All rights reserved.","subitem_rights_language":"en"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Pentraxin 3","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"inflammation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Aged","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Aged, 80 and over","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"C-Reactive Protein","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Case-Control Studies","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Disease Progression","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Female","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Heart Failure","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Humans","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Inflammation Mediators","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Male","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Middle Aged","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Predictive Value of Tests","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Probability","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Prognosis","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Proportional Hazards Models","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Reference Values","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Risk Assessment","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Sensitivity and Specificity","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Serum Amyloid P-Component","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Severity of Illness Index","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Statistics, Nonparametric","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Survival Analysis","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Vasculitis","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Background: Pentraxin 3 (PTX3) is a novel inflammatory marker produced by endothelial cells, smooth muscle cells and macrophages. The purpose of the present study was to examine the clinical significance of plasma PTX3 levels in patients with heart failure. Methods: We measured plasma PTX3 levels in 196 patients with heart failure and 60 control subjects without heart failure by sandwich ELISA. Patients were prospectively followed during a median follow-up period of 655 days with the end points of cardiac death or progressive heart failure requiring re-hospitalization. Results: Plasma PTX3 concentrations were higher in patients with heart failure than in control subjects (P < 0.0001) and increased as the severity of NYHA functional class advanced (P < 0.0001). A total of 63 cardiac events occurred during a follow-up period, and cardiac event free rate was markedly lower in patients with high PTX3 levels than in those with normal PTX3 levels (44.7% vs. 89.2%, P < 0.0001). The multivariate Cox proportional hazard analysis demonstrated that plasma PTX3 level, but not high sensitive C-reactive protein, was the independent predictor of cardiac events (hazard ratio 1.20, 95% confidence interval 1.03-1.40, P = 0.0162). Patients were divided into 4 groups based on plasma PTX3 values from 1st to 4th quartile. The highest 4th quartile of plasma PTX3 levels was associated with the highest risk of cardiac events (9.23-fold compared to the 1st quartile). Conclusions: Plasma PTX3 level provides important prognostic information for the risk stratification of patients with heart failure.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"Mosby, Inc.","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0002-8703","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"1097-6744","subitem_source_identifier_type":"EISSN"},{"subitem_source_identifier":"AA00048341","subitem_source_identifier_type":"NCID"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2008-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"81","bibliographicPageStart":"75","bibliographicVolumeNumber":"155","bibliographic_titles":[{"bibliographic_title":"American Heart Journal","bibliographic_titleLang":"en"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1016/j.ahj.2007.08.013","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"18082493","subitem_relation_type_select":"PMID"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2010-06-08"}],"displaytype":"detail","filename":"AmHeartJ_155_p75.pdf","filesize":[{"value":"375.9 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://fmu.repo.nii.ac.jp/record/2000008/files/AmHeartJ_155_p75.pdf"},"version_id":"836183ea-7333-4e4b-98cd-2dc9137d05ee"}]},"item_title":"Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure","item_type_id":"40002","owner":"8","path":["1730783669761"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-06-08"},"publish_date":"2010-06-08","publish_status":"0","recid":"2000008","relation_version_is_last":true,"title":["Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2025-01-07T06:27:00.183068+00:00"}